$0.14
(2.68%)
Add to watchlist
Create an alert
Stocks and Shares ISAAbeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
Company Information
About this company
Key people
Vishwas Seshadri
President, Chief Executive Officer, Director
Joseph W. Vazzano
Chief Financial Officer
Brendan O Malley
General Counsel
Michael Amoroso
Chairman of the Board
Leila Alland
Independent Director
Mark J. Alvino
Independent Director
Faith L. Charles
Independent Director
Eric Crombez
Independent Director
Click to see more
Key facts
- Shares in issue54.19m
- EPICABEO
- ISINUS00289Y2063
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$279.63m
- Employees136
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.